Flexion Therapeutics Inc (NASDAQ:FLXN)‘s stock had its “buy” rating reaffirmed by equities researchers at Northland Securities in a report issued on Wednesday. They presently have a $40.00 price objective on the specialty pharmaceutical company’s stock. Northland Securities’ price target would suggest a potential upside of 51.00% from the stock’s current price.

FLXN has been the subject of several other research reports. Royal Bank Of Canada reissued a “buy” rating and set a $44.00 price target on shares of Flexion Therapeutics in a report on Friday, July 7th. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 13th. Cantor Fitzgerald set a $40.00 price objective on Flexion Therapeutics and gave the company a “buy” rating in a research report on Monday, June 12th. BMO Capital Markets reaffirmed a “buy” rating on shares of Flexion Therapeutics in a research report on Tuesday, June 27th. Finally, Janney Montgomery Scott reiterated a “buy” rating and set a $35.00 price objective (up from $30.00) on shares of Flexion Therapeutics in a research note on Wednesday, July 12th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $31.50.

Shares of Flexion Therapeutics (NASDAQ:FLXN) opened at 26.49 on Wednesday. Flexion Therapeutics has a 12 month low of $15.93 and a 12 month high of $29.41. The company’s market capitalization is $845.16 million. The stock’s 50 day moving average price is $24.20 and its 200 day moving average price is $22.44.

Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.91) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, analysts forecast that Flexion Therapeutics will post ($3.74) EPS for the current year.

WARNING: “Flexion Therapeutics Inc (FLXN) Receives “Buy” Rating from Northland Securities” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/04/flexion-therapeutics-inc-flxn-receives-buy-rating-from-northland-securities.html.

In related news, insider Yamo Deniz bought 3,000 shares of the stock in a transaction dated Friday, September 1st. The shares were purchased at an average price of $24.15 per share, with a total value of $72,450.00. Following the completion of the acquisition, the insider now owns 5,000 shares of the company’s stock, valued at $120,750. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. In the last quarter, insiders have bought 5,375 shares of company stock worth $131,575. Company insiders own 15.98% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in FLXN. Ardsley Advisory Partners bought a new stake in Flexion Therapeutics in the 2nd quarter worth approximately $3,338,000. Wasatch Advisors Inc. raised its holdings in shares of Flexion Therapeutics by 58.7% during the 2nd quarter. Wasatch Advisors Inc. now owns 1,018,219 shares of the specialty pharmaceutical company’s stock worth $20,588,000 after acquiring an additional 376,745 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of Flexion Therapeutics by 69.4% during the 2nd quarter. Public Employees Retirement System of Ohio now owns 41,644 shares of the specialty pharmaceutical company’s stock valued at $842,000 after acquiring an additional 17,066 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its position in shares of Flexion Therapeutics by 13.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 63,520 shares of the specialty pharmaceutical company’s stock valued at $1,284,000 after acquiring an additional 7,667 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Flexion Therapeutics by 3.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,802 shares of the specialty pharmaceutical company’s stock valued at $441,000 after acquiring an additional 811 shares during the last quarter. Institutional investors and hedge funds own 83.26% of the company’s stock.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Stock Ratings for Flexion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc and related stocks with our FREE daily email newsletter.